Hip Fracture, Osteoporotic Hip Fracture, Sepsis
Conditions
Keywords
Monocyte Distribution Width (MDW), Geriatric Patients, Inflammatory Biomarkers, Postoperative Mortality, Postoperative Morbidity, C-reactive Protein, Procalcitonin, Antithrombin III, Hip Fracture
Brief summary
Hip fracture is a common injury in older adults and is often associated with serious complications, longer hospital stays, and increased risk of death. One of the most important causes of poor outcomes after hip fracture surgery is infection, including severe infections such as sepsis. Early identification of patients at higher risk for complications could help improve treatment and survival. This study aims to examine whether a blood test parameter called Monocyte Distribution Width (MDW), along with other commonly used inflammatory markers, can help predict complications and survival in elderly patients with hip fracture. MDW is measured as part of a routine complete blood count and has shown promise in the early detection of infection and systemic inflammation. Approximately 100 patients aged 65 years or older who are admitted to the hospital with a low-energy hip fracture will be included in this study. Blood tests will be performed at hospital admission, after surgery, and at other time points as part of standard clinical care. These tests include routine blood counts and inflammatory markers such as C-reactive protein (CRP), procalcitonin (PCT), antithrombin III, and MDW. No additional invasive procedures are required beyond standard medical care. Researchers will collect information about each patient's medical history, overall health status, and daily activity level before the fracture. Patients will be followed after surgery to assess complications, length of hospital stay, and survival at 1 month, 3 months, and 1 year. The results of this study may help determine whether MDW can be used as a simple and reliable marker to identify patients at higher risk of complications or death after hip fracture. This could support earlier intervention, closer monitoring, and improved care for elderly patients with hip fractures in the future.
Interventions
None listed
Sponsors
National and Kapodistrian University of Athens
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥65 years * Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture) * Admission to General Hospital of Attica KAT * Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers
Exclusion criteria
* Age \<65 years * High-energy trauma-related hip fractures * Pathological fractures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | Up to 12 months postoperatively. | Assessment of all-cause mortality in geriatric patients with low-energy hip fracture and its association with Monocyte Distribution Width (MDW) values measured at admission and during hospitalization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative morbidity | From postoperative day 1 through study completion, an average of 1 year. | Assessment of postoperative morbidity, including infectious and non-infectious complications, and its association with Monocyte Distribution Width (MDW) and other inflammatory markers (C-reactive protein, procalcitonin, antithrombin III). |
| Incidence of sepsis | From postoperative day 1 through study completion, an average of 1 year. | Occurrence of sepsis during hospitalization or postoperative follow-up, evaluated in relation to MDW values and other inflammatory biomarkers. |
| Change in Monocyte Distribution Width (MDW) over time | From hospital admission through hospital discharge, up to 14 days postoperatively. | Evaluation of changes in MDW values from admission through the postoperative period and at discharge, and their association with clinical outcomes. |
| Length of hospital stay | From the date of hospital admission until hospital discharge, assessed up to 30 days. | Duration of hospitalization measured in days and its association with MDW and inflammatory marker levels. |
Countries
Greece
Contacts
CONTACTEfstathios Chronopoulos
CONTACTLamprini Agapitou
STUDY_DIRECTOREfstathios Chronopoulos
KAT General Hospital, Athens Greece
Outcome results
None listed